Trevi Therapeutics, Inc. has announced significant advancements regarding its investigational therapy, Haduvio™ (oral nalbuphine ER), aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). This therapy is notable for being the first to demonstrate a statistically significant reduction in cough frequency in clinical trials across these patient populations, acting as a kappa agonist and mu antagonist (KAMA) to modulate the cough reflex both centrally and peripherally.

The clinical significance of Haduvio lies in addressing a high unmet need in chronic cough management, particularly for the estimated 140,000 U.S. patients with IPF, where two-thirds experience uncontrolled cough. Additionally, approximately 228,000 U.S. patients with non-IPF ILD and 2-3 million with RCC face similar challenges. Chronic cough can lead to severe morbidity, increased hospitalizations, and a marked decline in quality of life, emphasizing the urgent need for effective therapeutic options. Haduvio’s unique mechanism of action positions it as a potential game-changer in this therapeutic landscape.

The implications of Haduvio’s development extend to shaping future research and drug development timelines in the field of pulmonary medicine. By targeting the cough reflex arc and demonstrating efficacy in a previously underserved patient population, Trevi Therapeutics may catalyze increased investment and interest in novel therapeutic approaches for chronic cough. This could prompt a reevaluation of existing treatment paradigms and accelerate the pathway for similar investigational therapies aiming to address chronic cough and related conditions.

Source: globenewswire.com